Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
120 hedge funds and large institutions have $262M invested in Progenics Pharmaceuticals Inc in 2016 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 44 reducing their positions, and 16 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
1% less funds holding
Funds holding: 121 → 120 (-1)
10% less call options, than puts
Call options by funds: $833K | Put options by funds: $928K
18% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 44
32% less capital invested
Capital invested by funds: $383M → $262M (-$121M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.72M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.54M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.04M |
| 4 |
KAM
Kavi Asset Management
New York
|
+$1.01M |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$969K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.3M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$2.98M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.69M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.61M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.19M |
PGNX Hedge Fund Activity: Q1 2016 in Review
120 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q1 2016, worth a combined $262M — down 32% from $383M a quarter earlier.
Fund positioning in PGNX was balanced in Q1 2016: 16 funds opened new positions, 16 closed out, 36 added to existing stakes and 44 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.72M. The largest seller was Fidelity Investments, cutting an estimated $4.3M.
- 120 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q1 2016, down from 121 in Q4 2015.
- Funds reported $262M of Progenics Pharmaceuticals Inc stock for Q1 2016, down 32% quarter-over-quarter.
- 16 funds opened new Progenics Pharmaceuticals Inc positions in Q1 2016 and 16 closed out, a net change of 0 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q1 2016 was Millennium Management, an estimated $1.72M added.
- The largest Progenics Pharmaceuticals Inc seller in Q1 2016 was Fidelity Investments, an estimated $4.3M sold.
Based on aggregated 13F filings for Q1 2016.